Lv51
878 积分 2024-05-08 加入
什么时候才能不上班
Evolving therapeutic landscape of advanced hepatocellular carcinoma
4小时前
待确认
Multiple Myeloma: Diagnosis and Treatment
2天前
求助中
Peritoneal Metastases in Gastrointestinal Malignancies: A Review of the Pathophysiology of Metastasis and the Tumour Microenvironment
8天前
已完结
Does Malignant Ascites Define Prognosis in Gastric Cancer with Peritoneal Spread? A Systematic Review and Meta-analysis
8天前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
10天前
已完结
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
10天前
已完结
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
10天前
已完结
A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder
10天前
已关闭
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
14天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
14天前
已完结
皖公网安备34019202002308
